Ignite Creation Date:
2025-12-24 @ 12:11 PM
Ignite Modification Date:
2025-12-27 @ 9:32 PM
Study NCT ID:
NCT04902261
Status:
UNKNOWN
Last Update Posted:
2023-09-01
First Post:
2021-05-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
Sponsor:
Changhai Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-11-20
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-11-20
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-20
First Submit QC Date:
None
Study First Post Date:
2021-05-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-31
Last Update Post Date:
2023-09-01
Last Update Post Date Type:
ACTUAL